Compare Mesoblast Limited (MESO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs M&T Bank Corporation — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while M&T Bank Corporation trades at $248.07 (market cap $36.15B). The key difference: M&T Bank Corporation is far larger — about 16.7× Mesoblast Limited's market cap, and M&T Bank Corporation pays a 2.41% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | MTB | |
|---|---|---|
Market Cap | $2.17B | $36.15B |
Sector | Technology | Financials |
52-Week High | $20.96 | $254.04 |
52-Week Low | $12.88 | $178.63 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
M&T Bank (MTB) trades at $249.54, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals with a P/E of 13.19 and net income margin of 30.85%, supported by robust loan growth and net interest income as highlighted in Q2 2026 results. Analyst consensus is a buy with a $253.68 price target, though the majority of ratings are hold.
The outlook for MTB is positive due to solid earnings performance and healthy credit quality, but risks include elevated costs and macroeconomic pressures. Investment opportunity lies in its valuation and dividend yield, while investors should monitor expense management and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
